Payment overview · 2025
General Payments
$3,769.87
192 reported records · 22 companies
Healthcare provider profile · identity verified
Diego A Diaz, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · NEW YORK, NY · NPI 1942270467
Verified facts
What the public records show
CMS Open Payments records show Diego A Diaz, MD received $3,769.87 in general payments during 2025 across 192 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,014.13 | 26.9% | 43 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $881.40 | 23.4% | 58 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $339.78 | 9.0% | 22 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $316.34 | 8.4% | 16 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.53 | 4.2% | 6 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $157.64 | 4.2% | 13 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $111.57 | 3.0% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $104.89 | 2.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $101.15 | 2.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $86.68 | 2.3% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $72.82 | 1.9% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $59.16 | 1.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.15 | 1.6% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $58.92 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.18 | 1.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.54 | 1.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.88 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.19 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.52 | 0.7% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $23.44 | 0.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.56 | 0.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.40 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,769.87 | 192 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $497.12 | 39 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $427.91 | 20 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $412.11 | 16 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $384.28 | 19 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $320.35 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $271.40 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $225.91 | 15 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $157.64 | 13 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $156.62 | 8 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $104.89 | 3 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $101.15 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $86.68 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.58 | 4 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $72.82 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $69.35 | 3 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $59.19 | 2 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $59.16 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $58.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.54 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.52 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ipratropium Bromide | Ipratropium Bromide | 181 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 23 |
| Famotidine | Famotidine | 87 | 28 |
| Sertraline Hcl | Sertraline Hcl | 74 | 13 |
| Montelukast Sodium | Montelukast Sodium | 71 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 19 |
| Prednisone | Prednisone | 69 | 39 |
| Breo Ellipta | Fluticasone/Vilanterol | 64 | 20 |
| Furosemide | Furosemide | 64 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 16 |
| Omeprazole | Omeprazole | 62 | 17 |
| Losartan Potassium | Losartan Potassium | 58 | 18 |
| Gabapentin | Gabapentin | 57 | 17 |
| Meloxicam | Meloxicam | 57 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 16 |
| Simvastatin | Simvastatin | 54 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 18 |
| Eliquis | Apixaban | 48 | 14 |
| Metformin Hcl | Metformin Hcl | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | 16 |
| Arnuity Ellipta | Fluticasone Furoate | 42 | 13 |
| Azithromycin | Azithromycin | 39 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 16 |
| Rivastigmine | Rivastigmine | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 34 | 15 |
| Alprazolam | Alprazolam | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Meclizine Hcl | Meclizine Hcl | 32 | 13 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Lisinopril | Lisinopril | 27 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Azelastine Hcl | Azelastine Hcl | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Galantamine Er | Galantamine Hbr | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,769.87 · 192 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACTHAR, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, DUPIXENT, ELIQUIS, FARXIGA, FASENRA, GLASSIA, Hillrom - Vest System Model 105 Home Care, JASCAYD, LEQVIO, MOUNJARO, NEXLETOL, NUCALA, NURTEC ODT, OFEV, Ohtuvayre, PAXLOVID, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REPATHA, REXULTI, SMARTVEST, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, ZEPBOUND, Zemaira | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error